Goldman adds Vertex to U.S. Director’s Cut list; drops IBKR
Goldman Sachs added Vertex Pharmaceuticals to its monthly U.S. Director’s Cut list and removed Interactive Brokers. The list covers 20–25 high-conviction, Buy-rated U.S. stocks and is updated monthly via bottom-up fundamental analysis.
VRTX IBKR Goldman Sachs: Updates U.S.
Director's Cut List ⠀ · Goldman Sachs added Vertex Pharmaceuticals to its monthly U.S.
Director's Cut list and removed Interactive Brokers. · The list includes 20—25 high-conviction, Buy-rated U.S. stocks selected for differentiated views and attractive risk-adjusted return potential. · Goldman updates the list monthly based on bottom-up fundamental analysis; additions or removals do not necessarily indicate a change in analyst rating.